Company
GlioCART
Redefining hope for patients with glioblastoma
Also known as GlioCART GmbH
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- Allschwil, Switzerland
- Legal name
- GlioCART GmbH
Claim, correct or request removal
Record updated 28 September 2026
About
GlioCART addresses the key barriers in glioblastoma – immunosuppression and antigen escape – through its dual-action CAR-T therapy, targeting not only tumor cells but also reprogramming tumor-supporting myeloid cells into active immune effectors.
Funding snapshot
- Latest round
- Grant
Funding rounds
- Grant
- Recorded
Loading relationship preview